Jan 31, 2025, 10:34 AM – TLP WHITE
Key Takeaways:
-
US tariffs are likely to hit the healthcare sector in some fashion and tariffs on healthcare-related goods (including pharmaceuticals, medical technology and equipment) would only further drive up costs – especially for the lowest-end, generic drugs.
-
US tariffs on China and potentially Chinese companies abroad will only accelerate the decoupling of the healthcare industry globally, particularly if the US also seeks to restrict Chinese medical technology from reaching US shores through third-party countries via supply chain reviews and other similar non-tariff barriers.
-
The US may scale back its universal tariff on all imports to affect only certain countries or types of goods, but Indian and European Union (EU) pharmaceutical products, healthcare technology and equipment are unlikely to escape the tariffs, at least initially, raising costs and disrupting supply chains for the industry beyond just US restrictions on China.
-
Anti-NATO hacktivist groups may engage in disruptive attacks against health sector organizations in NATO countries in retaliation to new tariffs.
-
Health sector organizations, especially those using AI/ML systems to bolster research and development (R&D) may be at heightened risk of cyberespionage campaigns.
ImpactsofProposedUSImportTariffsontheGlobalHealthSector
Size : 1.9 MB Format : PDF
This report, published once a month, is an in-depth analysis of a geopolitical trend whose cascading consequences adversely impact the healthcare sector. This report is a joint endeavor between RANE and Health-ISAC. The guidance and insight within are designed to help members navigate particularly complex geopolitical developments with healthcare-specific analysis and mitigation strategies.
